Quchang Ouyang

机构：Central South University, Hunan Cancer Hospital, Hunan Provincial People's Hospital · ORCID：0000-0003-1233-6081

发表论文 133 篇 · 总被引 2721 次 · h-index 25

代表论文

• Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies (2025 · Journal of Hematology & Oncology · 被引 23)
• Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial (2024 · Journal of Translational Internal Medicine · 被引 18)
• ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). (2024 · Journal of Clinical Oncology · 被引 13)
• Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial (2025 · Journal of Clinical Oncology · 被引 12)
• Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial (2025 · 癌症：英文版 · 被引 9)
• Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 8)